請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77644
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林?輝(Feng-Huei Lin) | |
dc.contributor.author | Yu-Ting Chen | en |
dc.contributor.author | 陳郁婷 | zh_TW |
dc.date.accessioned | 2021-07-10T22:13:22Z | - |
dc.date.available | 2021-07-10T22:13:22Z | - |
dc.date.copyright | 2018-07-03 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-06-28 | |
dc.identifier.citation | [1] W.H. Organization, Obesity and overweight. WHO http://www.who.int/mediacentre/factsheets/fs311/en/, (2016).
[2] P. A., A.M.A. Recognizes obesity as a disease. The New York Times http://www.nytimes.com/2013/06/19/business/ama-recognizes-obesity-as-a-disease.html., (2013). [3] N.R.F. Collaboration, Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19· 2 million participants, The Lancet 387(10026) (2016) 1377-1396. [4] M. Ng, et al., Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013, The lancet 384(9945) (2014) 766-781. [5] T. Kelly, et al., Global burden of obesity in 2005 and projections to 2030, International journal of obesity 32(9) (2008) 1431. [6] W.H. Organization, Waist circumference and waist-hip ratio: Report of a WHO expert consultation, Geneva, 8-11 December 2008, (2011). [7] 台灣衛生福利部國民健康署, BMI 測試, http://health99.hpa.gov.tw/OnlinkHealth/Onlink_BMI.aspx, (2015). [8] National Center for Chronic Disease Prevention and Health Promotion, How is BMI interpreted for adults, https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html, (2017). [9] 台灣衛生福利部國民健康署, 健康防治網, https://obesity.hpa.gov.tw/TC/index.aspx, (2014). [10] H.-C. Chang, et al., Morbid obesity in Taiwan: Prevalence, trends, associated social demographics, and lifestyle factors, PloS one 12(2) (2017) e0169577. [11] 林庭語, 肥胖健康診療, 大展出版社有限公司, (2004). [12] V.S. Malik, et al., Global obesity: trends, risk factors and policy implications, Nature Reviews Endocrinology 9(1) (2013) 13-27. [13] T.-D. Kanneganti, V.D. Dixit, Immunological complications of obesity, Nature immunology 13(8) (2012) 707-712. [14] C.N. Lumeng, A.R. Saltiel, Inflammatory links between obesity and metabolic disease, The Journal of clinical investigation 121(6) (2011) 2111. [15] T. Lehnert, et al., Economic costs of overweight and obesity, Best practice & research Clinical endocrinology & metabolism 27(2) (2013) 105-115. [16] D. Withrow, D. Alter, The economic burden of obesity worldwide: a systematic review of the direct costs of obesity, Obesity reviews 12(2) (2011) 131-141. [17] A. Dee, et al., The direct and indirect costs of both overweight and obesity: a systematic review, BMC research notes 7(1) (2014) 242. [18] 許毓真, 產業技術評析:對抗肥胖-減肥用藥新進展,https://www.moea.gov.tw/MNS/doit/industrytech/IndustryTech.aspx?menu_id=13545&it_id=1, 台灣經濟部技術處, (2015). [19] 黃. 蕭伶茲, 黃偉新, 新減重藥物的發展, 家庭醫學與基層醫療 (2015). [20] J. Zhi, et al., Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers, The Journal of Clinical Pharmacology 35(11) (1995) 1103-1108. [21] A.P. Shukla, et al., Lorcaserin Hcl for the treatment of obesity, Expert opinion on pharmacotherapy 16(16) (2015) 2531-2538. [22] M. Misra, Obesity pharmacotherapy: current perspectives and future directions, Current cardiology reviews 9(1) (2013) 33-54. [23] S.Z. Yanovski, J.A. Yanovski, Long-term drug treatment for obesity: a systematic and clinical review, Jama 311(1) (2014) 74-86. [24] D. Haslam, Weight management in obesity–past and present, International journal of clinical practice 70(3) (2016) 206-217. [25] V.S. Hubbard, W.H. Hall, Gastrointestinal Surgery for Severe Obesity, Obesity surgery 1(3) (1991) 257-265. [26] H. Buchwald, D.M. Oien, Metabolic/bariatric surgery worldwide 2011, Obesity surgery 23(4) (2013) 427-436. [27] 減肥劑代謝手術中心, https://www.ntuh.gov.tw/obesity/service/SitePages/%E6%B8%9B%E9%87%8D%E5%A4%96%E7%A7%91%E4%BB%8B%E7%B4%B9.aspx, 台大醫院. [28] J.L. Colquitt, et al., Surgery for obesity, Cochrane Database Syst Rev 2(2) (2009). [29] U. Rohde, et al., Increased Postprandial Glucagon-like Peptide-1 Responses in Obese Patients with Type 2 Diabetes Implanted for 26 Weeks with the EndoBarrier Gastrointestinal Liner, DIABETES, AMER DIABETES ASSOC 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA, 2016, pp. A505-A505. [30] P. Sen Gupta, et al., One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion Using Endobarrieras an Adjunct to Glucagon-like Peptide-1 (GLP-1) Therapy in Suboptimally Controlled Type 2 Diabetes: A Randomised Controlled Trial, Novel Treatment for Diabetes-Focusing on GLP-1 and SGLT2, Endocrine Society2016, pp. PP15-1-PP15-1. [31] R. Schouten, et al., A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery, Annals of surgery 251(2) (2010) 236-243. [32] M. Tarnoff, et al., Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery, Surgical endoscopy 23(3) (2009) 650-656. [33] A. Levine, et al., Radiographic appearance of endoscopic duodenal-jejunal bypass liner for treatment of obesity and type 2 diabetes, Surgery for obesity and related diseases 5(3) (2009) 371-374. [34] 行政院衛生署、國家衛生研究院, 2020健康國民白皮書, 行政院衛生署出版, (2009). [35] 衛生福利部食品藥物管理署, 健康食品概說, https://www.fda.gov.tw/tc/sitecontent.aspx?sid=1776 (2015). [36] 衛生福利部食品藥物管理署, 衛生福利部審核通過之健康食品資料查詢, https://consumer.fda.gov.tw/Food/InfoHealthFood.aspx?nodeID=162#, (2017). [37] 經濟部技術處產業技術知識服務計畫, 食品產業年鑑-科技專案成果, (2015) P. 171~189. [38] M. Beysseriat, et al., Preliminary study of the influence of dietary fiber on the properties of oil-in-water emulsions passing through an in vitro human digestion model, Food Hydrocolloids 20(6) (2006) 800-809. [39] A. Usman, et al., Chitin and chitosan based polyurethanes: A review of recent advances and prospective biomedical applications, International journal of biological macromolecules 86 (2016) 630-645. [40] R.W. Coughlin, et al., Chitosan in crab shell wastes purifies electroplating wastewater, Environmental Progress & Sustainable Energy 9(1) (1990) 35-39. [41] Yoshinori Kato#, Hiraku Onishi and Yoshiharu Machida, <Application of Chitin and Chitosan Derivatives in the Pharmaceutical.pdf>, Current Pharmaceutical Biotechnology (2003). [42] B.K. Paweł Wydro, * and Katarzyna Ha¸ c-Wydro, <Chitosan-as-a-Lipid-Binder : A Langmuir Monolayer Study of Chitosan-Lipid Interactions.pdf>, Biomacromolecules (2007). [43] 衛生福利部食品藥物管理署, 可供食品使用原料彙整一覽表, https://consumer.fda.gov.tw/Food/Material.aspx?nodeID=160. [44] D. Knorr, Use of chitinous polymers in food: a challenge for food research and development, Food Technology (USA) (1984). [45] M.F. Goosen, Applications of Chitan and Chitosan, CRC Press1996. [46] M.N.R. Kumar, A review of chitin and chitosan applications, Reactive and functional polymers 46(1) (2000) 1-27. [47] M. Deacon, Metal chelation in separation science, Dublin City University, 1994. [48] M.P. Sheetz, et al., Cell migration: regulation of force on extracellular-matrix-integrin complexes, Trends in cell biology 8(2) (1998) 51-54. [49] S.V. Hudson, et al., Modeling the Kinetics of Integrin Receptor Binding to Hepatic Extracellular Matrix Proteins, Scientific Reports 7 (2017). [50] P.C. Brooks, et al., Requirement of vascular integrin alpha-v beta-3 for angiogenesis, Science 264(5158) (1994) 569-572. [51] M.D. Pierschbacher, E. Ruoslahti, Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule, Nature 309(5963) (1984) 30-33. [52] E. Ruoslahti, M.D. Pierschbacher, New perspectives in cell adhesion: RGD and integrins, Science 238(4826) (1987) 491-498. [53] S.L. Bellis, Advantages of RGD peptides for directing cell association with biomaterials, Biomaterials 32(18) (2011) 4205-10. [54] Wikipedia, Arginylglycylaspartic acid, https://en.wikipedia.org/wiki/Arginylglycylaspartic_acid. [55] K. Boulle, et al., A Review of the Metabolism of 1, 4‐Butanediol Diglycidyl Ether–Crosslinked Hyaluronic Acid Dermal Fillers, Dermatologic Surgery 39(12) (2013) 1758-1766. [56] A. Subramanian, H.Y. Lin, Crosslinked chitosan: its physical properties and the effects of matrix stiffness on chondrocyte cell morphology and proliferation, Journal of biomedical materials research Part A 75(3) (2005) 742-753. [57] S.K. Roy, et al., Crosslinked hydrogel beads from chitosan, Google Patents, 1998. [58] M. Karlsson, et al., Method for manufacturing a shaped crosslinked hyaluronic acid product, Google Patents, 2013. [59] G.K. Heber, N.P.J. Stamford, Cross-linked polysaccharide gels, Google Patents, 2007. [60] Wikipedia, 1,4-Butanediol, https://en.wikipedia.org/wiki/1,4-Butanediol. [61] Y. Maezaki, et al., Hypocholesterolemic effect of chitosan in adult males, Bioscience, Biotechnology, and Biochemistry 57(9) (1993) 1439-1444. [62] W. Xia, et al., Biological activities of chitosan and chitooligosaccharides, Food Hydrocolloids 25(2) (2011) 170-179. [63] X. Liu, et al., Effects of chitosan, O-carboxymethyl chitosan and N-[(2-hydroxy-3-N, N-dimethylhexadecyl ammonium) propyl] chitosan chloride on lipid metabolism enzymes and low-density-lipoprotein receptor in a murine diet-induced obesity, Carbohydrate polymers 85(2) (2011) 334-340. [64] M. Sugano, et al., Hypocholesterolemic action of chitosans with different viscosity in rats, Lipids 23(3) (1988) 187-191. [65] J. LeHoux, F. Grondin, Some effects of chitosan on liver function in the rat, Endocrinology 132(3) (1993) 1078-1084. [66] J. Zhang, et al., A comparative study on hypolipidemic activities of high and low molecular weight chitosan in rats, International journal of biological macromolecules 51(4) (2012) 504-508. [67] R.F. Wallin, E. Arscott, A practical guide to ISO 10993-5: Cytotoxicity, Medical Device and Diagnostic Industry 20 (1998) 96-98. [68] Wikipedia, Ninhydrin, https://en.wikipedia.org/wiki/Ninhydrin. [69] R.L. Science, Cell Proliferation Reagent WST-1. [70] T.B. INC., 生細胞・死細胞同時染色キット, http://catalog.takara-bio.co.jp/product/basic_info.php?unitid=U100007244. [71] H.J. Kim, et al., Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow, Lab on a Chip 12(12) (2012) 2165-2174. [72] I. Maschmeyer, et al., A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents, Lab on a Chip 15(12) (2015) 2688-2699. [73] 衛生福利部食品藥物管理署, 健康食品之不易形成體脂肪保健功效評估方法, https://www.fda.gov.tw/tc/newsContent.aspx?id=10365&chk=137995ba-5cee-491a-ae3e-d407e1f55263, (2012). [74] F. Guidance, Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, Rockville, MD, USA (2005). [75] I. Charhouf, et al., Characterization of a dialdehyde chitosan generated by periodate oxidation, biosensors 16 (2014) 18. [76] M.X. Weinhold, et al., Strategy to improve the characterization of chitosan for sustainable biomedical applications: SAR guided multi-dimensional analysis, Green Chemistry 11(4) (2009) 498-509. [77] M.-H. Ho, et al., Preparation and characterization of RGD-immobilized chitosan scaffolds, Biomaterials 26(16) (2005) 3197-3206. [78] A. Rezania, et al., Bioactivation of metal oxide surfaces. 1. Surface characterization and cell response, Langmuir 15(20) (1999) 6931-6939. [79] C.N. Mhurchu, et al., Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials, Obesity reviews 6(1) (2005) 35-42. [80] M.S. Rodriguez, L.E. Albertengo, Interaction between chitosan and oil under stomach and duodenal digestive chemical conditions, Bioscience, biotechnology, and biochemistry 69(11) (2005) 2057-2062. [81] M. Giknis, C. Clifford, Clinical laboratory parameters for Crl: CD (SD) rats, Charles River Laboratories (2006) 1-14. [82] Z.-Z. Han, et al., Reference data of the main physiological parameters in control Sprague-Dawley rats from pre-clinical toxicity studies, Laboratory Animal Research 26(2) (2010) 153-164. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77644 | - |
dc.description.abstract | 肥胖和過重為異常或過多的脂肪積累,伴隨賀爾蒙失衡、神經傳導激素分泌缺乏,連帶影響身體其他功能的疾病。目前調節體重的方法以健康食品為多數人的最佳選擇,但市面上的健康食品仍有服用順從度低、單方功效等相當程度上的缺點。本研究旨在於研發並評估RGD胜肽接枝幾丁聚醣,仿造醫療器材Endobarrier®套筒形成物理性阻隔減少油脂攝取模式,透過RGD與腸胃上皮細胞的整合素受器達到中長期貼附,並評估減肥功效。
使用BDDE開環接枝RGD胜肽於幾丁聚醣,由比較接枝前後的FTIR官能基圖譜和NMR一維氫譜確認接枝成功。RGD功能性測試顯示短胜肽可抵擋消化液而保有原特徵峰;寧海德林測試量化接枝上的RGD濃度,結果顯示接枝上的RGD胜肽具其功效和接枝效率。 RGD胜肽接枝幾丁聚醣依據ISO 10993進行WST-1測試細胞活性;並使用LIVE & DEAD 測試說明實驗材料具良好生物相容性。並以WST-1篩選材料最佳濃度進行細胞貼附試驗,顯示修飾後的幾丁聚醣較有良好的貼附性。動物實驗以飼料誘發肥胖模型,RGD接枝幾丁聚醣確實能達到體重控制之效,並受劑量高低影響。比較接枝前後幾丁聚醣的體重控制成效,推論經過修飾後的幾丁聚醣較未修飾幾丁聚醣具有控制體重之功效。由體重變化與標準體重增加率得到幾丁聚醣在四周內的體重增加率約為62%、四周後為70%;高低劑量的RGD胜肽接枝幾丁聚醣內臟體脂率相較控制組達顯著差異,但高低劑量間無差異。血清、血液和尿液結果則顯示數值正常。綜合上述結果,RGD胜肽接枝幾丁聚醣膠為一安全性高,適用於短效、降低內臟脂肪以達控制體重的健康食品。未來仍可改量此幾丁聚醣膠,期待研發出安全、長效並兼具全方位效果的抗減肥健康食品。 | zh_TW |
dc.description.abstract | Obesity and overweight has become a serve issue all over the world. It has been defined as a disease with excessive fat accumulation causing hormone imbalances. Health food is the optimal one; however, it remains low compliance. The aim of this study is to develop and evaluate a RGD-conjugated chitosan gel as an orally administrated health food supplements for anti-obesity treatments. The gel is designed to be like Endobarrier®, as a biocompatible, low risk, middle-term lasting covering the surface of gastrointestinal tract to form an absorption barrier.
The FTIR and NMR spectrum indicated that RGD has been conjugated successfully on chitosan; Ninhydrin and RGD functionality test showed large amount of RGD peptide conjugated and effective. In vitro data suggested good biocompatibility. In vivo animal studies showed the gel can lower the weight and reduce the body fat rate affected by dosage. Comparing the weight control effects of conjugated and nonconjugated chitosan, it was deduced that the modified chitosan was effective in controlling weight comparing with the original. Taken together, the RGD conjugated chitosan gel is a safe, suitable for short-term, reducing visceral fat rate health food to control weight. In the future, it is expected to develop a safe and long-term effective anti-obesity chitosan by further modification. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T22:13:22Z (GMT). No. of bitstreams: 1 ntu-107-R05548033-1.pdf: 3063837 bytes, checksum: 984c5b4eb26fc0aac0adda33de7e1e74 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract iii 目錄 iv 圖目錄 viii 表目錄 x 公式目錄 xi 名詞縮寫目錄 xii 第一章 緒論 1 1.1 前言 1 1.2 肥胖症 1 1.2.1 肥胖的定義 1 1.2.2 肥胖的成因 4 1.2.3 肥胖的併發症 5 1.2.4 肥胖對於經濟的損失 6 1.3 調節體重的方法 7 1.3.1 運動飲食控制 7 1.3.2 健康食品與代餐 7 1.3.3 減肥藥物 7 1.3.4 手術治療 11 1.4 健康食品在台灣 14 1.4.1 健康食品法規 14 1.4.2 市售不易形成體脂肪和調節血脂之健康食品 16 1.5 研究目的 16 第二章 基礎理論 17 2.1 膳食纖維對於食物於腸道消化的影響 17 2.2 幾丁質(Chitin)與幾丁聚醣(Chitosan) 18 2.2.1 幾丁聚醣之製備 19 2.2.2 幾丁聚醣材料特性及應用 19 2.3 精氨酸-甘氨酸-天門冬氨酸(Arginine-glycine-aspartic acid, RGD) 22 2.4 1,4-丁二醇二縮水甘油醚(1,4-Butanediol diglycidyl ether, BDDE) 23 2.5 幾丁聚醣對體脂肪與血脂影響機制 25 第三章 實驗步驟與方法 26 3.1 實驗儀器 26 3.2 實驗藥品 27 3.3 實驗架構 28 3.4 材料製備與分析 29 3.4.1 材料製備方法 29 3.4.2 傅里葉轉換紅外光譜(Fourier-transform Infrared, FTIR) 29 3.4.3 核磁共振光譜(Nuclear magnetic resonance spectroscopy, NMR) 29 3.4.4 RGD功能性測試(RGD functionality test) 30 3.4.5 寧海德林測試(Ninhydrin Test) 30 3.5 生物相容性試驗(Biocompatibility) 31 3.5.1 WST-1細胞活性(Water Soluble Tetrazolium Salt-1, WST-1) 31 3.5.2 細胞存活染色(Live & Dead Staining) 32 3.6 體外(In Vitro)試驗 34 3.6.1 材料濃度測試(Material concentration test) 34 3.6.2 細胞貼附試驗(Cell Adhesion Test) 34 3.7 體內(In Vivo)試驗 35 3.7.1 肥胖動物模型 (Obesity animal model) 35 3.7.2 體重變化與標準體重增加率(Weight change & Standard weight gain rate) 35 3.7.3 內臟體脂肪率和器官觀察(Body visceral fat rate & Organs) 36 3.7.4 血清生化分析(Serum chemistry analysis) 36 3.7.5 血液與尿液分析(Hematology & Urinalysis) 36 3.8 統計學方法(Statistic method) 37 第四章 結果與討論 38 4.1 材料分析 38 4.1.1 傅里葉轉換紅外光譜分析(Fourier-transform infrared, FTIR) 38 4.1.2 核磁共振光譜(Nuclear magnetic resonance spectroscopy, NMR) 39 4.1.3 RGD功能性測試(RGD functionality test) 40 4.1.4 寧海德林測試(Ninhydrin test) 41 4.2 生物相容性試驗(Biocompatibility) 42 4.2.1 WST-1細胞活性(Water soluble tetrazolium salt-1, WST-1) 42 4.2.2 細胞存活染色(Live & Dead staining) 43 4.3 體外(In Vitro)試驗 44 4.3.1 材料濃度測試(Material concentration test) 44 4.3.2 細胞貼附試驗(Cell Adhesion Test) 45 4.4 體內(In Vivo)試驗 46 4.4.1 體重和動物模型(Animal model & Weight) 46 4.4.2 體重變化與標準體重增加率(Weight change & Standard weight gain rate) 48 4.4.3 內臟體脂肪率和器官觀察(Body visceral fat rate & Organs) 49 4.4.4 血清生化分析(Serum chemistry analysis) 50 4.4.5 血液與尿液分析(Hematology & Urinalysis) 51 第五章 結論 53 參考文獻 54 | |
dc.language.iso | zh-TW | |
dc.title | 製備並評估RGD胜肽接枝幾丁聚醣膠作為口服健康食品形成物理阻隔抗肥胖症之功效 | zh_TW |
dc.title | The Preparation and Evaluation of a RGD-Conjugated Chitosan Gel as an Orally Administrated Health Food Supplements forming Physical Barrier for Anti-Obesity | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 許志雄(Chi-Shiung Hsi),陳景欣(Gin-Shin Chen),柯承志(Cherng-Jyh Ke) | |
dc.subject.keyword | 肥胖,健康食品,生醫材料,RGD胜?,幾丁聚醣,交聯, | zh_TW |
dc.subject.keyword | Obesity,Health food,Biomaterials,Chitosan,RGD peptide,Crosslink, | en |
dc.relation.page | 61 | |
dc.identifier.doi | 10.6342/NTU201801099 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2018-06-29 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R05548033-1.pdf 目前未授權公開取用 | 2.99 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。